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Friedreich ataxia (FRDA) is the most common recessive ataxia in the Caucasian population
and is characterized by a mixed spinocerebellar and sensory ataxia frequently associating
cardiomyopathy. The disease results from decreased expression of the FXN gene coding
for the mitochondrial protein frataxin. Early histological and biochemical study of the
pathophysiology in patient’s samples revealed that dysregulation of iron metabolism is
a key feature of the disease, mainly characterized by mitochondrial iron accumulation and
by decreased activity of iron-sulfur cluster enzymes. In the recent past years, considerable
progress in understanding the function of frataxin has been provided through cellular
and biochemical approaches, pointing to the primary role of frataxin in iron-sulfur cluster
biogenesis. However, why and how the impact of frataxin deficiency on this essential
biosynthetic pathway leads to mitochondrial iron accumulation is still poorly understood.
Herein, we review data on both the primary function of frataxin and the nature of the
iron metabolism dysregulation in FRDA. To date, the pathophysiological implication of the
mitochondrial iron overload in FRDA remains to be clarified.
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INTRODUCTION
Ataxias are a heterogeneous group of disorders characterized
by loss of coordination due to the degeneration of the neu-
ronal networks closely linked to cerebellar function. Friedreich’s
ataxia (FRDA) is the most prevalent form of hereditary ataxia in
Caucasians, accounting for 75% of ataxia with onset prior to 25
years of age (Cossee et al., 1997). FRDA is characterized by pro-
gressive spinocerebellar and sensory ataxia (Harding, 1981). The
symptoms associated with the disease include the absence of deep
tendon reflexes, dysarthria, pyramidal signs, muscular weakness,
and positive extensor plantar response (Harding, 1981; Pandolfo,
2009). The neurological symptoms result from progressive degen-
eration of large sensory neurons in the dorsal root ganglia (DRG)
and their axonal projection in the posterior columns, as well as
from degeneration of the spinocerebellar and corticospinal tracts
of the spinal cord (Koeppen and Mazurkiewicz, 2013). The den-
tate nucleus of the cerebellum is also affected and accounts for
the cerebellar phenotype (Koeppen, 2011). FRDA is also charac-
terized by primary non-neurological manifestations, in particular
hypertrophic cardiomyopathy and increased incidence of diabetes
(Harding and Hewer, 1983). The cardiomyopathy associated with
FRDA is due to the natural transition from hypertrophy to dila-
tion. The latter promotes cardiomyocytes death and replacement
of contractile cells by fibrotic tissue leading to severe systolic
and diastolic dysfunction (Tsou et al., 2011; Payne and Wagner,
2012; Weidemann et al., 2012). Lethal congestive heart failure
and supraventrivular arrhythmias is the primary mode of death
in∼60% of patients with FRDA (Harding, 1981; Tsou et al., 2011;
Weidemann et al., 2012).
The mutated gene in FRDA is localized on the long arm of
chromosome 9 (9q21.11) and codes for a small mitochondrial
protein called frataxin (FXN) (Campuzano et al., 1996, 1997;
Koutnikova et al., 1997). All FRDA patients carry at least one allele
with an expansion of a GAA-triplet repeat in the first intron of
the FXN gene. Most patients are homozygous for this mutation,
but a few patients (4%) are compound heterozygous for the GAA
expansion and a classical mutation (nonsense, missense, dele-
tions, insertions) leading to loss of FXN function (Campuzano
et al., 1996; Cossee et al., 1999; Gellera et al., 2007). Normal
chromosomes contain up to 40 GAA repeats, whereas disease-
associated alleles contain 100 to more than 1500 GAA repeats,
most commonly ∼600–900. This GAA expansion leads to tran-
scriptional silencing of FXN through a mechanism involving
modifications of the chromatin structure of the locus, resulting
in expression of a structurally and functionally normal frataxin
but at levels that are estimated at ∼5–30% of normal (reviewed
in Gottesfeld, 2007; Schmucker and Puccio, 2010). As demon-
strated in knockout animals, complete absence of frataxin leads
to early embryonic death (Cossee et al., 2000). The rare non-
GAAmutations in FXN that have been associated with FRDA lead
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to production of non-functional or partially functional proteins
(Correia et al., 2008). In most cases, compound heterozygous
patients are clinically indistinguishable from patients that are
homozygous for the GAA expansions, but a few missense muta-
tions (e.g., G130V, D122Y, R165P, L106S) in compound het-
erozygous patients cause atypical or milder clinical presentations
(Cossee et al., 1999; Gellera et al., 2007).
The genetic basis of FRDA in humans raises challenges for
modeling the disease in other species. Despite the difficulty in
generating perfect FRDA models, a multitude of complemen-
tary models have been generated enabling significant advances
in understanding the function of frataxin, the pathophysiology
of the disease and some of the mechanisms implicated in GAA-
based silencing (reviewed in Martelli et al., 2012b; Perdomini
et al., 2013). Due to its high evolutionary conservation, the
effect of FXN depletion has been modeled in diverse organ-
isms, including yeast (Babcock et al., 1997; Foury and Cazzalini,
1997), invertebrates such as C. elegans (Vazquez-Manrique et al.,
2006; Ventura et al., 2006; Zarse et al., 2007) and Drosophila
(Anderson et al., 2005; Llorens et al., 2007), and in mice (Puccio
et al., 2001; Miranda et al., 2002; Simon et al., 2004; Al-Mahdawi
et al., 2006; Martelli et al., 2012a). However, due to the complex-
ity of the clinical phenotype of individuals with FRDA and the
species specificity in regulation of certain fundamental pathways,
in particular iron metabolism, mouse models or mammalian
cell culture models are probably better suited to understand the
pathophysiological mechanisms involved in the disease.
IRON DYSREGULATION IN FRIEDREICH ATAXIA
Early characterization of the pathophysiology in individuals with
FRDA provided evidence of a link between frataxin deficiency
and cellular iron metabolism dysregulation. Indeed, Lamarche
and colleagues were the first to report the presence of granu-
lar iron deposits in cardiomyocytes of FRDA patients (Lamarche
et al., 1980). After the discovery of the disease-causing gene,
the generation of the yeast strain deficient for the yeast frataxin
homolog, Yfh1, (Yfh1) showed that iron could accumulate in
large amount within mitochondria (Babcock et al., 1997; Foury
and Cazzalini, 1997). In mammals, mitochondrial iron accu-
mulation and deposits were observed in the conditional mouse
model reproducing the cardiac phenotype (MCKmouse) (Puccio
et al., 2001). Iron metabolism dysregulation was also observed
in heart autopsies of individuals with FRDA (Michael et al.,
2006; Ramirez et al., 2012). Biochemical studies of heart biopsies
also demonstrated a deficit in mitochondrial iron-sulfur (Fe-
S) cluster-containing enzymes (aconitase and respiratory chain
complexes I-III) (Rotig et al., 1997). Finally, the presence of
markers of oxidative damage in blood and urine samples was
reported (Emond et al., 2000; Schulz et al., 2000; Bradley et al.,
2004), although contradictory results from patient data have been
reported (Di Prospero et al., 2007; Myers et al., 2008; Schulz et al.,
2009). Altogether, these observations led to the early assumption
of a pathophysiological implication of iron-dependent pathways
in FRDA.
The presence of mitochondrial iron accumulation in FRDA-
affected neurons is however less clear. Both dentate nucleus and
dorsal root ganglions (DRGs) of individuals with FRDA have
been studied to investigate iron dysregulation. Dentate nucleus
is an iron-rich cerebellar structure that shows signs of neurode-
generation in patients with FRDA (Koeppen, 2011). Despite a
report of difference in the MRI signals that suggests an over-
all increase of iron in the dentate nucleus of individuals with
FRDA (Boddaert et al., 2007), no difference in iron concen-
trations was measured using autopsies (Koeppen et al., 2007).
However, modification of the expression of iron-related proteins
such as transferrin receptor 1 (TFR1), ferritins (FRTs) and fer-
roportin (FPN) were observed, thereby suggesting a change in
iron metabolism (Koeppen et al., 2007). Further investigations
using X-ray fluorescence (XRF) suggested that iron was relocat-
ing from dying neurons to microglia of dentate nucleus (Koeppen
et al., 2012). Similarly, DRGs from individuals with FRDA do not
show overall iron concentrations above normal (Koeppen et al.,
2009). However, the expression of FRTs, the iron-storage proteins,
increases as satellite cells surrounding affected DRG neurons pro-
liferate (Koeppen et al., 2009, 2013), thus suggesting again a
redistribution of iron from dying neurons to satellite cells.
Although these observations suggest that iron is released dur-
ing neuronal degeneration and then stored by surrounding glial
cells, they do not give any indication on the primary involvement
of iron dysregulation in the neuropathophysiology. In particular,
mitochondrial iron deposits have never been reported in neurons
from FRDA individuals and were not observed in an inducible
conditional mouse model reproducing the neuronal phenotype
(Prp mice) (Simon et al., 2004).
To understand the role and pathophysiological implication of
iron in the disease, it is therefore essential to understand the func-
tion of frataxin and how its impairment can lead to cellular iron
dysregulation.
IRON AND FRATAXIN FUNCTION
FRATAXIN AS AN IRON-BINDING PROTEIN
Frataxin is a highly conserved protein present from gram-
negative bacteria to eukaryotes, including yeast and mammals
(Figure 1A). Frataxin is localized within the eukaryotic mito-
chondria and is ubiquitously expressed in mammals. The struc-
ture of frataxin is unique and conserved in between species:
frataxin is a small globular acidic protein composed of a long N-
terminal alpha helix and a short C-terminal alpha helix that both
interact with a central beta-sheet structure (Figure 1B) (Musco
et al., 2000).
Although bacterial (CyaY), yeast (Yfh1), and mammalian
(FXN) frataxins all exist as soluble monomers, early in vitro stud-
ies of bacterial CyaY and yeast Yfh1 showed that the proteins are
able to form oligomeric spheroidal structures in the presence of
excess iron (Adamec et al., 2000; Gakh et al., 2002; Layer et al.,
2006; Adinolfi et al., 2009). These oligomeric structures can cap-
ture up to 50–75 atoms of iron, in a similar way as ferritin. Due to
its property in scavenging iron, oligomeric frataxin was initially
proposed to act as ferritins by providing bio-available iron within
mitochondria (Adamec et al., 2000; Cavadini et al., 2002). This
hypothesis was further sustained by the capacity of mitochon-
drial ferritin to complement for frataxin deficiency in the Yfh1
yeast strain and in HeLa cells (Campanella et al., 2004; Zanella
et al., 2008). However, further experiments in yeast showed that
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FIGURE 1 | Sequences and structure of frataxin. (A) Sequence alignment
of human, mouse, yeast, and bacterial frataxin. The non-conserved
N-terminal parts of human, mouse, and yeast frataxins contain the
mitochondrial targeting sequence of the protein. The arrows indicate the
intermediate and mature forms of human FXN that are obtained during the
two-step maturation process in vivo (Schmucker et al., 2008). The red dots
indicate acidic residues of the N-terminal alpha helix of human and bacterial
frataxins that are involved in the primary iron binding site of the monomeric
protein. (B) Three dimensional structure of human frataxin obtained by NMR
(1LY7) (Musco et al., 2000).
expression of human mitochondrial ferritin only partially rescues
theYfh1 strain through amechanism that does not overlap with
frataxin function (Sutak et al., 2012). In addition, modulating
the expression of Yfh1 in a yeast mutant strain that accumu-
lates iron in mitochondria, in a similar way as the Yfh1 strains,
does not modify iron bio-availability (Seguin et al., 2010). The
relevance of the in vivo function of oligomeric frataxin is also
questioned by in vitro data showing that bacterial CyaY forms
iron-rich oligomeric structures only under aerobic conditions
and high ionic strengths (Adinolfi et al., 2002; Layer et al., 2006).
Furthermore, yeast Yfh1 bearing a point mutation that prevents
oligomerization can rescue the Yfh1 strain (Aloria et al., 2004),
therefore indicating that oligomerization is not required to fulfill
the main function of frataxin in vivo.
In higher eukaryotes, the oligomerization process does not
appear to be fully conserved. Frataxin is encoded by a nuclear
gene and synthesized as a precursor protein (FXN1−210) that is
then matured in two steps within the mitochondrial matrix to
give an intermediate form (FXN42−210) and the major mature
form (FXN81−210) (Condo et al., 2007; Schmucker et al., 2008)
(Figure 1A). Only the precursor and intermediate forms of FXN
can form oligomers in an iron-independent way, whereas mature
human FXN is not prone to oligomerization (O’neill et al., 2005;
Prischi et al., 2009). Furthermore, in vivo experiments using
mouse fibroblasts deleted for the endogenous murine frataxin
showed that the expression of the mature human FXN81−210 is
sufficient to promote cell survival (Schmucker et al., 2011), thus
indicating that oligomerization is not a process required for the
primary and essential function of mammalian frataxin in vivo.
Although the functional relevance of an iron-rich oligomeric
frataxin is questionable, there is clear evidence that monomeric
frataxin can also bind iron in vitro. Several iron-binding sites
have been characterized depending on the oxidative state of iron
(Fe2+ or Fe3+) and the origin of the frataxin proteins (CyaY, Yfh1,
or human FXN) (Yoon and Cowan, 2003; Bou-Abdallah et al.,
2004; Cook et al., 2006; Yoon et al., 2007; Huang et al., 2008).
A primary iron-binding site appears however to be conserved and
involves residues of the acidic ridge localized within the first alpha
helix of frataxin (Figure 1). The site binds Fe2+ with a disso-
ciation constant (Kd) within the micromolar range (3–55μM)
(Yoon and Cowan, 2003; Nair et al., 2004; Cook et al., 2006) but
seems to be poorly specific as other cations were shown to also
bind CyaY (Pastore et al., 2007).
FUNCTION OF FRATAXIN IN Fe-S CLUSTER BIOGENESIS
The capacity of frataxin to bind iron and the evidence of an
iron metabolism dysregulation in individuals with FRDA and in
Yfh1 yeast strains led to the assumption that frataxin plays a key
role in the mitochondrial iron metabolism. Further biochemical
and interaction studies provided several hypotheses. Interactions
with mitochondrial aconitase, ferrochelatase and proteins of the
mitochondrial Fe-S cluster machinery were reported (Gerber
et al., 2003; Bulteau et al., 2004; Yoon and Cowan, 2004; Bencze
et al., 2007), and the hypothesis of frataxin being an iron provider
to various iron-dependent mitochondrial pathways was brought
forward. However, interactions with aconitase and ferrochelatase
are still poorly characterized and were reported not to be repro-
ducible (Schmucker et al., 2011). To date, only the interaction
of frataxin with proteins involved in the mitochondrial Fe-S
biogenesis have been extensively and convincingly characterized.
Fe-S clusters are inorganic redox-active protein cofactors that
are present in almost all living organisms. They play cardinal
roles in various functions throughout the cell, including elec-
tron transport in the respiratory complexes and DNA repair
or metabolism. Although Fe-S clusters can adopt different con-
figurations, [Fe2S2] and [Fe4S4] clusters are the most frequent
Fe-S clusters in eukaryotes. De novo biosynthesis of Fe-S clusters
occurs within mitochondria (reviewed in Lill, 2009; Beilschmidt
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and Puccio, 2014). The first step involves the assembly of a Fe-S
cluster on a scaffold protein ISCU (Isu in yeast) from inorganic
iron and sulfur. A cysteine desulfurase complex NFS1/ISD11 pro-
vides the sulfur through a persulfide intermediate. ISCU and
NFS1/ISD11 interact and form a ternary ISCU/NFS1/ISD11 com-
plex with a most likely α2β2γ4 stoichiometry (Schmucker et al.,
2011; Colin et al., 2013). Once the cluster is assembled on ISCU,
it is transferred to acceptor proteins with the help of additional
components of the mitochondrial Fe-S cluster machinery, such as
the HSCB/HSPA9 chaperone system or proteins (e.g., ISCA1/2)
that provide Fe-S cluster to a subset of mitochondrial proteins
(Figure 2). Alternatively, a still uncharacterized intermediate pro-
vided by the early Fe-S cluster machinery is exported from the
mitochondria to the cytosol via the ABCB7 transporter where it
is used by the cytosolic Fe-S cluster assembly machinery (CIA
machinery) to generate Fe-S clusters for cytosolic and nuclear
acceptor proteins (reviewed in Lill, 2009) (Figure 2).
The first hints for the primary involvement of frataxin in Fe-
S cluster biogenesis came from the characterization of the cardiac
mouse model mimicking the FRDA cardiomyopathy, as Fe-S clus-
ter dependent enzymes were affected prior to the appearance
of the heart dysfunction and the mitochondrial iron accumu-
lation (Puccio et al., 2001; Seznec et al., 2004; Martelli et al.,
2007) (Figure 3A). In parallel, early phylogenetic studies pre-
dicted a role of frataxin in Fe-S cluster metabolism (Huynen
et al., 2001). The implication of frataxin in Fe-S cluster biogen-
esis was later confirmed in yeast depleted for Yfh1 (Duby et al.,
2002; Muhlenhoff et al., 2002). Furthermore, an iron-dependent
interaction of Yfh1 with Nfs1 and Isu1 was reported in yeast
(Gerber et al., 2003), while in vitro reconstitution experiments
FIGURE 2 | Schematic view of the Fe-S cluster machinery and the
IRP-mediated cellular iron regulation. De novo Fe-S cluster biogenesis
occurs within mitochondria and involves assembly of inorganic sulfur and
iron on a scaffold protein ISCU. Iron is imported into the mitochondria by
mitoferrins (MFRN). The process of Fe-S cluster assembly occurs within
a complex consisting of NFS1-ISD11, the cysteine desulfurase providing
the sulfur, ISCU and eventually frataxin (FXN), which regulates the NFS1
activity and the entry of iron within the complex (Colin et al., 2013). The
process also needs electrons (e–) that may be provided by a
mitochondrial ferredoxin (FDX2). Once assembled the cluster on ISCU is
transferred to acceptor proteins with the help of additional proteins, such
as the chaperones HSCB and HSPA9, ISCA proteins, IBA57, NFU1,
BOLA3, and NUBPL (reviewed in Lill, 2009; Beilschmidt and Puccio,
2014). Alternatively, a still uncharacterized compound (X) provided by the
mitochondrial machinery is exported to the cytosol via ABCB7 and is
used by the cytosolic Fe-S cluster assembly machinery (CIA machinery)
to assemble Fe-S clusters for cytosolic and nuclear acceptor proteins.
Among the cytosolic Fe-S cluster acceptors, IRP1 is a regulator of
cellular iron metabolism. In normal conditions, IRP1 binds a Fe-S cluster
to become an aconitase devoid of regulatory capacity. IRP2 exists only
as an apoprotein and is regulated through proteasomal degradation
mediated by the iron sensor protein FBXL5 (Salahudeen et al., 2009;
Vashisht et al., 2009). Both IRPs can regulate the expression of key
genes involved in iron metabolism, such as transferrin receptor 1 (TFR1),
ferritins (FRTs), and the iron exporter ferroportin (FPN), by binding a
specific mRNA motif called IRE. Depending on the location of the IRE
compared to the open reading frame (ORF), IRPs can increase (+) or
decrease (−) protein expression, thus controlling cellular iron import and
storage (reviewed in Anderson et al., 2012). DMT1: divalent metal
transporter involved in iron import.
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FIGURE 3 | MCK mouse model. (A) Phenotypic characteristics of the MCK
mouse model: MCK mice develop progressive hypertrophic
cardiomyopathy characterized by progressive left ventricule (LV) dysfunction
and hypertrophy starting around 5 weeks of age. The cardiomyopathy leads
to cell death and fibrosis. MCK mice prematurely dye around 11 weeks.
Fe-S cluster deficit is a primary feature in the mouse pathology with
significant differences observed in 4 weeks old mice. Mitochondrial iron
(mit-Fe) accumulation is observed in the later stage of the disease. (B)
Electron microscopy picture obtained from a heart sample of a 7 weeks old
MCK mouse showing mitochondrial abnormalities, in particular collapse
cristae and electron-dense deposits (arrows) corresponding to
mitochondrial iron deposits. mf, myofiber. (C) Semi-nested PCR on cDNA
from heart samples of 8 weeks old control and deleted MCK mice was
performed as described (Santambrogio et al., 2007) to assess mitochondrial
ferritin (FTMT) expression. Total RNA from tissue was extracted using
Trizol® reagent (Life Technologies) and submitted (+) or not (−) to reverse
transcription (RT). Testis cDNA was used as positive control for Ftmt
expression, and a classical PCR to amplify mitochondrial aconitase (Aco2)
cDNA was carried out as a control for reverse transcription and loading.
Samples without reverse transcription (RT–) were used as control for
specific PCR amplification.
showed that human FXN could transfer iron to ISCU (Yoon
and Cowan, 2003) and that bacterial CyaY could provide iron
for Fe-S cluster formation (Layer et al., 2006). Altogether, these
results suggested that frataxin might be the iron donor for the
assembly of the Fe-S cluster in vivo. However, data from mam-
mals, yeast, and bacteria were quite controversial as to the direct
frataxin protein partner in Fe-S biogenesis (Gerber et al., 2003;
Layer et al., 2006; Shan et al., 2007; Li et al., 2009). Recently,
these results were reconciled by independent work using mam-
malian recombinant proteins showing that frataxin interacts with
a preformed complex composed of NFS1, ISCU, and ISD11 (Tsai
and Barondeau, 2010; Schmucker et al., 2011). A similar com-
plex was also reported in bacteria (Prischi et al., 2010). In line
with results obtained with the bacterial CyaY suggesting that
frataxin is a regulator of the Fe-S clusters synthesis (Adinolfi
et al., 2009), the binding of frataxin in the mammalian system
was shown to stabilize the complex and to activate the cysteine
desulfurase activity (Tsai and Barondeau, 2010; Colin et al., 2013).
Moreover, although the formation of the complex was shown to
be iron-independent (Schmucker et al., 2011), frataxin appears
to concomitantly activate the cysteine desulfurase activity and to
control iron entry within the complex (Colin et al., 2013). More
recently, the biochemical characterization of the successive steps
of the cysteine desulfurase activity in yeast provided evidence
that frataxin triggers a conformational change that modifies the
substrate-binding site of the enzyme (Pandey et al., 2013). All
these results therefore indicate that frataxin, by controlling both
iron entry and sulfide production, is essential in the process of
Fe-S cluster assembly during the initial stage of the biogenesis.
However, how frataxin controls iron entry within the complex still
need to be determined. In particular, residues that define the pri-
mary iron-binding site of the protein in vitro were also shown to
be involved in the interaction with the cysteine desulfurase and/or
the ISCU/NFS1/ISD11 complex (Prischi et al., 2010; Schmucker
et al., 2011). Hence, the in vivo implication of this iron-binding
site needs to be further investigated.
FROM IRON-SULFUR CLUSTER DEFICIT TO MITOCHONDRIAL
IRON ACCUMULATION
Although the recent advances point to a primary role of frataxin
in Fe-S cluster biogenesis, the cellular mechanism that links
frataxin deficiency to mitochondrial iron overload remains elu-
sive. However, mitochondrial iron accumulation is not specific to
frataxin deficiency, but rather appears as a general hallmark of
primary Fe-S deficiency, as it has been observed in various yeast
strains deleted for different genes involved in Fe-S cluster biogen-
esis (Kispal et al., 1997; Garland et al., 1999; Schilke et al., 1999;
Lange et al., 2000; Voisine et al., 2001). Furthermore, mutations in
human genes implicated in Fe-S cluster biogenesis have recently
been identified as disease-causing genes (reviewed in Beilschmidt
and Puccio, 2014), and some of the associated disorders are also
characterized by mitochondrial iron accumulation. Mutations
in the scaffold protein ISCU lead to myopathy with lactic aci-
dosis with different severity, also known as Swedish myopathy
(Mochel et al., 2008; Olsson et al., 2008; Kollberg et al., 2009).
The major mutation, due to a founder effect in Sweden, induces
a muscle-specific cryptic splice site that leads to a truncated
protein (Mochel et al., 2008; Olsson et al., 2008). In muscle biop-
sies, iron labeling (Perl’s staining) showed accumulation of iron
within mitochondria (Mochel et al., 2008; Kollberg et al., 2009).
Mutations in ABCB7 are associated with X-linked sideroblastic
anemia with ataxia, a condition that is characterized by the pres-
ence of iron-rich perinuclear mitochondria within erythroblasts
(sideroblasts) (Allikmets et al., 1999; Bekri et al., 2000). Similarly,
a mutation in GLRX5, a protein linked to Fe-S cluster biogene-
sis, although its function is still unclear (Rodriguez-Manzaneque
et al., 2002), was identified in a patient presenting sideroblastic
anemia (Camaschella et al., 2007). Interestingly, mutations linked
to human disease in proteins involved in the delivery of Fe-S
cluster to a subset of mitochondrial proteins (e.g., NFU1, IBA57,
BOLA3—see Figure 2) are not associated with iron accumulation
(reviewed in Beilschmidt and Puccio, 2014).
It is most likely that the pathways leading to iron dysregulation
and mitochondrial iron accumulation are shared among the dif-
ferent disease linked to primary Fe-S cluster biogenesis. Although
the link between Fe-S cluster deficit and iron metabolism has
been observed in both yeast and mammals, it is unlikely that
the mechanisms involved in mitochondrial iron accumulation are
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strictly conserved between the two species, as cellular iron home-
ostasis involves different modes of regulation in yeast and higher
eukaryotes.
CELLULAR IRON REGULATION IN MAMMALS
In mammals, the Iron Regulatory Proteins (IRP) 1 and 2 largely
regulates cellular iron homeostasis. IRP1 and IRP2 are cytosolic
translational regulators that control the expression of proteins
involved in iron handling and distribution (Figure 2), as well
as targeting other transcripts that are not directly involved in
iron metabolism such as HIF2α and mitochondrial aconitase
(reviewed in Hentze et al., 2010; Anderson et al., 2012). IRP1
and 2 can bind specific mRNA motifs, called Iron Responsive
Elements (IRE), thereby influencing protein expression by reg-
ulating either protein translation or mRNA metabolism. Indeed,
when the IRE is located in the 5′ UTR, binding of IRPs blocks
translation, whereas the formation of an IRP/IRE complex in
the 3′ UTR leads to an increase half-life of the mRNA, there-
fore increasing translation. Transferrin receptor 1 (TFR1), impli-
cated in cellular iron import, and the ferritins (FRTs), involved
in cytosolic iron storage, are key proteins regulated by IRPs
(Figure 2). The mRNA of TFR1 contains several IRE motifs
within the 3′ UTR, whereas mRNAs coding for FRTs contain
an IRE motif in the 5′ UTR. Although IRP1 and IRP2 exhibit
some functional redundancy as both proteins can control TFR1
and FRTs expressions, some IRE sequence specificities have been
reported (Ke et al., 1998; Anderson et al., 2013). However, the
activity of IRP1 and IRP2 are mostly regulated differently. When
cytosolic iron concentration increases, the iron-binding protein
FBXL5 targets IRP2 to ubiquitination and proteasomal degrada-
tion (Figure 2) (Salahudeen et al., 2009; Vashisht et al., 2009).
However, although IRP1 can also be targeted by FBXL5, its
IRE-binding activity is mainly negatively regulated through the
insertion of a [Fe4-S4] cluster leading to a protein with cytosolic
aconitase activity devoid of IRE-binding activity (Figure 2) (Haile
et al., 1992a,b).
IRP1 and IRP2 have been shown to have overlapping func-
tions as observed in knockout mouse models (Galy et al., 2005;
Anderson et al., 2013; Ghosh et al., 2013), however, IRP2 is con-
sidered as the main iron regulator under normal physiological
conditions as IRP1 exists mainly as an aconitase (Meyron-Holtz
et al., 2004; Moroishi et al., 2011) (Figure 2).
THE NATURE OF THE MITOCHONDRIAL ACCUMULATED IRON
To date, no data provide a clear answer on the nature of the iron
that is accumulated in affected mitochondria, but few interest-
ing hints are available. The analysis of heart tissues from MCK
mice by electron microscopy showed the presence of electron-
dense particles within the mitochondrial matrix (Figure 3B) that
correlated with iron accumulation (Puccio et al., 2001). Similar
structures were observed in mitochondria of heart tissue from
individuals with FRDA (Michael et al., 2006) and in the liver con-
ditional knockout mouse (ALB mouse) (Martelli et al., 2012a). In
FRDA patients’ samples, histological analysis suggested that mito-
chondrial ferritin (FTMT) might be involved in the formation of
the iron-rich structures (Michael et al., 2006). However, recent
data obtained in MCK mice suggested that FTMT is not involved
since iron was reported to be mostly present as mineral non-
ferritin aggregates (Whitnall et al., 2012). In addition, despite
a similar pattern of iron deposits as in patients (Figure 3B),
no Ftmt mRNA could be detected in both the heart of MCK
mice (Figure 3C) or the liver of ALB mice (AM and HP, unpub-
lished results) using a semi-nested PCR protocol developed to
specifically assess Ftmt expression (Santambrogio et al., 2007).
These results further question the potential role of FTMT in the
molecular pathophysiology.
Interestingly, the iron-rich aggregates observed inmousemod-
els and patient samples are reminiscent of the mitochondrial
phosphate-iron nano-particles that were identified in Yfh1
yeasts (Lesuisse et al., 2003), as well as in the yeast strains deleted
for Yah1 and Atm1 (the homologs of ferredoxin or ABCB7,
respectively) (Miao et al., 2008, 2009). The formation of these
aggregates in yeast mitochondria lead to a decrease of available
iron that affects heme biosynthesis (Lesuisse et al., 2003; Seguin
et al., 2010).
MODIFICATIONS OF IRON-RELATED PROTEIN AND GENE EXPRESSION
IN THE CARDIAC MOUSE MODEL
Although the characterization of the cardiac MCK mouse
model and cellular models deficient in frataxin have provided
several clues on the nature of iron dysregulation occurring
after frataxin deficiency (Seznec et al., 2005; Whitnall et al.,
2008, 2012; Huang et al., 2009), available data are sometimes
contradictory.
The variations in activity, protein and mRNA expressions of
key genes implicated in iron regulation and distribution that
have been reported in MCK mice are shown in Table 1. IRP1
was shown to be activated into its IRE-binding form in MCK
mice (Seznec et al., 2005), in agreement with the primary role
of frataxin in Fe-S cluster biogenesis. This was also observed
in frataxin knockdown experiments using HeLa cells (Stehling
et al., 2004). Accordingly, similar observations were made in
knockdown experiments or knockout animals targeting other
proteins of the Fe-S cluster machinery (Biederbick et al., 2006;
Fosset et al., 2006; Pondarre et al., 2006; Wang et al., 2007).
Furthermore, ferritin L (FRTL) mRNA and protein levels were
shown to progressively increase in MCK mice (Seznec et al.,
2005). More recently, an increase of transferrin receptor 1 (TFR1)
protein expression concomitant to a decrease of expression of
ferroportin (FPN), the cellular iron exporter, was reported in
FXN-deficient mice (Whitnall et al., 2008; Huang et al., 2009),
thus suggesting an overall increase of the iron import capacity.
This modification of iron import was confirmed by 59Fe import
experiments (Whitnall et al., 2008). However, in contradiction
with the reported increase of FRTL levels (Seznec et al., 2005),
both ferritin L and H displayed decreased protein levels when
compared to control animals, and most strikingly, no differ-
ence in IRP1 IRE-binding activity could be observed (Whitnall
et al., 2008, 2012). As iron metabolism is a tightly regulated
pathway, caution in comparing animal data raised in different
laboratories have to be taken [differential animal food, circa-
dian rhythm, and experimental condition before sacrifice (diet
intake)]. Notably, in the latter reports, the mobility shift assays
show that IRP1 is almost fully activated into its IRE-binding
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Table 1 | Modifications in iron-related gene expression and activity in MCK mice.
IRE-binding activity References
IRP1 UP (5, 7, 10) Seznec et al., 2005
Similar (4, 9, 10)# Whitnall et al., 2008, 2012
IRP2 UP (4, 9, 10) Whitnall et al., 2008, 2012
mRNA level References Protein level References
IRP1 DOWN (10) Seznec et al., 2005 n.a
IRP2 Similar (3, 5, 10) Seznec et al., 2005 UP (8, 5) Whitnall et al., 2012
TFR1 UP (4, 9, 10) Whitnall et al., 2008; Huang et al., 2009 UP (4, 9, 10) Whitnall et al., 2008; Huang et al., 2009
FRTL UP (5, 10) Seznec et al., 2005 UP (5, 8, 10) Seznec et al., 2005
Similar (4, 9, 10) Whitnall et al., 2008; Huang et al., 2009 DOWN (4, 9, 10) Whitnall et al., 2008; Huang et al., 2009
FRTH DOWN (5)* Seznec et al., 2005 DOWN (4, 9, 10) Whitnall et al., 2008, 2012; Huang et al., 2009
Similar (4, 9, 10) Whitnall et al., 2008; Huang et al., 2009
FPN DOWN (9)£ Whitnall et al., 2008 DOWN (9)£ Whitnall et al., 2008
DOWN (4, 9) Huang et al., 2009 DOWN (4, 9) Huang et al., 2009
MFRN2 UP (4, 10) Huang et al., 2009 n.a
FTMT Similar (4, 9, 10) Whitnall et al., 2008; Huang et al., 2009 DOWN (4, 9, 10) Whitnall et al., 2008, 2012; Huang et al., 2009
Not detectable Figure 3C
“UP” indicates increase of expression or activity in Fxn-deleted mice compared to control mice, “DOWN” means decrease and “Similar,” no detectable change.
Ages (in weeks) corresponding to the observations are indicated in brackets.
#IRP1 almost fully activated in both control and deleted MCK mice.
*Mitochip array data; n.a: data not available.
£No difference was observed at 4 weeks.
form in both control and deleted mice (Whitnall et al., 2008,
2012), in contradiction with IRP1 being essentially an aconi-
tase in normal physiological conditions. Furthermore, the authors
also provided evidence that IRP2 is more active in FXN-deleted
animals (Whitnall et al., 2008, 2012), thus indicating a deple-
tion of iron within the cytosol leading to reduced proteasomal
degradation of IRP2. Cytosolic iron depletion was confirmed
by iron concentration measurements after tissue fractionation
(Whitnall et al., 2008), although these measurements do not
discriminate between the available cytosolic iron pool and the
one trapped within ferritins, which were shown under the same
experimental conditions to be decreased (Whitnall et al., 2008).
More interestingly, the mRNA level of mitoferrin-2 (MFRN2),
the mitochondrial iron transporter, is significantly increased in
MCK mice (Huang et al., 2009). A similar increase of MFRN2
mRNA has been observed in skeletal muscle biopsies from ISCU
myopathy patients (Crooks et al., 2014). These results suggest the
existence of a Fe-S cluster-dependent regulation of mitochon-
drial iron import, whether direct or indirect, that may control
mitochondrial iron overload. However, whether up-regulation of
MFRN2 is sufficient to explain mitochondrial iron accumulation
in FXN-deficient mice is not known.
CONCLUSION AND PERSPECTIVES
To understand the consequence of mitochondrial iron overload
on the pathophysiology of FRDA is of particular interest in
the context of therapeutic approaches for FRDA. Early report
suggested that the iron accumulation generated toxic free radi-
cals through Fenton reaction, therefore implying iron chelators
as possible therapeutic agents. Although it is most likely that
reactive oxygen species play a role in FRDA, the primary involve-
ment as well as the importance of reactive oxygen species in the
pathophysiology are still a matter of debate in the field.
Recently, Deferiprone, an iron chelator that may cross the
blood brain barrier, has been used in preclinical and clinical
studies for FRDA, but the results were somehow puzzling as dif-
ferent doses showed opposite effects, if any (reviewed in Pandolfo
and Hausmann, 2013), therefore further questioning the ratio-
nale behind the use of chelation therapy in FRDA. In line with
these results, the data obtained with the MCK mouse model fur-
ther indicates that both cellular and mitochondrial iron imports
are increased in the absence of frataxin. Does it mean that cells,
and in particular mitochondria, are in iron deprivation rather
than facing toxic iron accumulation? This question may seem
counterintuitive when total mitochondrial iron is measured in
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FRDA models, but the characterization of the accumulated iron
in frataxin-deficient cells provide further evidence that iron may
not be biologically available within mitochondria. Hence, the role
of chelation therapies should be to target this non-available iron
to make it available again for biological processes, rather than
depleting iron from the cell as it is expected in other disorders
of iron overload.
The primary function of frataxin in Fe-S cluster biogenesis is
now on the way of being fully elucidated through the biochemical
characterization of the complex in which it is involved. Attention
is also brought to the understanding of the cellular consequences
of frataxin deficiency. In particular, the mechanism leading to
mitochondrial iron accumulation, and most importantly, the
consequences of this accumulation on the pathophysiology is
under investigation. All together, these data will be valuable for
the evaluation and design of new therapeutic approaches that may
(or not) use iron chelators. The recent identification of several
other human genetic disorders linked to primary Fe-S cluster defi-
ciency and displayingmitochondrial iron accumulation, as well as
the development of the corresponding cellular and animal models
will clearly be an asset to address these questions.
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